Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors.

Publisher: International Research and Cooperation Association for Bio & Socio-Sciences Advancement Country of Publication: Japan NLM ID: 101502754 Publication Model: Print Cited Medium: Internet ISSN: 1881-7823 (Electronic) Linking ISSN: 18817815 NLM ISO Abbreviation: Biosci Trends Subsets: MEDLINE

Original Publication: Tokyo : International Research and Cooperation Association for Bio & Socio-Sciences Advancement

Integrase Inhibitors/*adverse effects ; Integrase Inhibitors/*therapeutic use; Animals ; Clinical Trials as Topic ; Humans ; Treatment Outcome

More than 30 drugs for antiretroviral therapy (ART), including integrase inhibitors (INIs), have been approved by the U.S. Food and Drug Administration (FDA) as of 2017. Integrase is the third essential enzyme in the cycle of human immunodeficiency virus (HIV) replication. INIs can effectively inhibit the replication of HIV and HIV is less prone to develop resistance to INIs clinically. Previous studies based on 7 phase III clinic trials indicate that INIs have satisfactory efficacy and tolerability in patients infected with HIV. The latest advances in INIs indicate that: i) dolutegravir (DTG)-based regimens are more efficacious, tolerable, and safer forms of first-, second-, and third-Line ART; ii) current studies have indicated that DTG monotherapy fails both virologically and clinically; and iii) whether the most cost-effective treatment for DTG is to replace efavirenz (EFV) as a first-line ART, to replace protease inhibitors (PIs) in second-line ART, or to replace both as a monotherapy is unclear. Given these circumstances, further study of INIs in terms of drug interactions, dose reduction, drug convenience, and drug costs is warranted.

Keywords: Dolutegravir; antiretroviral therapy; drug resistance; monotherapy

0 (Integrase Inhibitors)

Date Created: 20170915 Date Completed: 20180514 Latest Revision: 20180514

20250114

10.5582/bst.2017.01194

28904329